Compare MDA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDA | ACAD |
|---|---|---|
| Founded | 1969 | 1993 |
| Country | Canada | United States |
| Employees | 4000 | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.8B |
| IPO Year | 2026 | 2000 |
| Metric | MDA | ACAD |
|---|---|---|
| Price | $32.24 | $21.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 22 |
| Target Price | ★ $37.50 | $30.55 |
| AVG Volume (30 Days) | 689.6K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | $12.11 | $18.80 |
| Revenue Next Year | $11.03 | $11.70 |
| P/E Ratio | ★ N/A | $9.58 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $23.23 | $14.18 |
| 52 Week High | $37.45 | $28.35 |
| Indicator | MDA | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 49.87 | 48.87 |
| Support Level | $23.23 | $20.81 |
| Resistance Level | $33.75 | $22.03 |
| Average True Range (ATR) | 1.75 | 0.61 |
| MACD | 0.23 | 0.06 |
| Stochastic Oscillator | 44.63 | 48.95 |
MDA Space Ltd is a developer and manufacturer of technology and services to the space industry. It is an international space mission partner and robotics, satellite systems, and geo-intelligence pioneer. It is engaged in communications satellites, Earth and space observation, space exploration, and infrastructure. The Company collaborates and partners with governments and space agencies, commercial space companies, and defence and aerospace prime contractors in the space industry. Geographically, it generates the majority of its revenue from Canada.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.